Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Ovarian Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
46 drugs · 161 active trials
11 drugs · 195 active trials
5 drugs · 126 active trials
Data updated 14 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Fludarabine | Phase 2 | Phase 2 | 16 | 7 | 0 | 35 | 0 | — | — | 2007-08 |
| Aldesleukin | Phase 2 | Phase 2 | 9 | 4 | 0 | 27 | 0 | — | — | 1996-02 |
| Fulvestrant | Phase 2 | Phase 2 | 8 | 6 | 0 | 17 | 0 | — | — | 2007-06 |
| Fluorouracil | Phase 2 | Phase 2 | 7 | 5 | 0 | 12 | 0 | — | — | 1997-11 |
| Abemaciclib | Phase 2 | Phase 2 | 7 | 5 | 0 | 8 | 0 | — | — | Oct 16, 2020 |
| Ipilimumab | Phase 2 | Phase 2 | 4 | 0 | 0 | 14 | 0 | — | — | 2002-03 |
| Leucovorin | Phase 2 | Phase 2 | 4 | 2 | 0 | 9 | 0 | — | — | 1991-10 |
| Adavosertib | Phase 2 | Phase 2 | 4 | 0 | 0 | 7 | 0 | — | — | Jul 26, 2011 |
| Cemiplimab | Phase 2 | Phase 2 | 4 | 4 | 0 | 7 | 0 | — | — | May 21, 2018 |
| Decitabine | Phase 2 | Phase 2 | 4 | 1 | 0 | 7 | 0 | — | — | 2007-07 |
| Ipatasertib | Phase 2 | Phase 2 | 4 | 1 | 0 | 5 | 0 | — | — | Aug 17, 2015 |
| Irinotecan | Phase 2 | Phase 2 | 3 | 2 | 0 | 10 | 0 | — | — | 1997-10 |
| Cabozantinib | Phase 2 | Phase 2 | 3 | 1 | 0 | 5 | 0 | — | — | Nov 6, 2012 |
| Sacituzumab Govitecan | Phase 2 | Phase 2 | 3 | 2 | 0 | 5 | 0 | — | — | Dec 17, 2012 |
| Capivasertib | Phase 2 | Phase 2 | 3 | 1 | 0 | 4 | 0 | — | — | Dec 1, 2010 |
| Trastuzumab Emtansine | Phase 2 | Phase 2 | 3 | 0 | 0 | 4 | 0 | — | — | Aug 17, 2015 |
| Avutometinib And Defactinib | Phase 2 | Phase 2 | 3 | 1 | 0 | 3 | 0 | — | — | Dec 21, 2020 |
| Binimetinib | Phase 2 | Phase 2 | 3 | 1 | 0 | 3 | 0 | — | — | Aug 17, 2015 |
| Ribociclib | Phase 2 | Phase 2 | 2 | 2 | 0 | 7 | 0 | — | — | Jul 8, 2016 |
| Tremelimumab | Phase 2 | Phase 2 | 2 | 0 | 0 | 6 | 0 | — | — | Dec 19, 2013 |
| Cobimetinib | Phase 2 | Phase 2 | 2 | 0 | 0 | 5 | 0 | — | — | Jul 10, 2018 |
| Selinexor | Phase 2 | Phase 2 | 2 | 1 | 0 | 5 | 0 | — | — | Apr 9, 2014 |
| Berzosertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | Aug 25, 2016 |
| Sapanisertib | Phase 2 | Phase 2 | 2 | 0 | 0 | 3 | 0 | — | — | May 20, 2014 |
| Selumetinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | Dec 17, 2007 |
| Toripalimab | Phase 2 | Phase 2 | 2 | 1 | 0 | 3 | 0 | — | — | May 3, 2022 |
| Camizestrant | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Nov 12, 2020 |
| Datopotamab Deruxtecan | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Nov 12, 2020 |
| Hydroxychloroquine | Phase 2 | Phase 2 | 2 | 2 | 0 | 2 | 0 | — | — | Mar 8, 2023 |
| Neratinib | Phase 2 | Phase 2 | 2 | 1 | 0 | 2 | 0 | — | — | Aug 24, 2020 |
| Eribulin | Phase 2 | Phase 2 | 1 | 1 | 0 | 7 | 0 | — | — | 2006-04 |
| Aflibercept | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2006-05 |
| Celecoxib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2002-06 |
| Cetuximab | Phase 2 | Phase 2 | 1 | 1 | 0 | 5 | 0 | — | — | 2003-09 |
| Vismodegib | Phase 2 | Phase 2 | 1 | 0 | 0 | 5 | 0 | — | — | 2008-12 |
| Copanlisib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | Aug 17, 2015 |
| Dasatinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 4 | 0 | — | — | 2008-06 |
| Panitumumab | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 2009-04 |
| Regorafenib | Phase 2 | Phase 2 | 1 | 1 | 0 | 4 | 0 | — | — | 2014-12 |
| Tislelizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 3 | 0 | — | — | Apr 1, 2021 |
| Tivozanib | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | Jun 6, 2013 |
| Bendamustine | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | 2009-02 |
| Entrectinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Nov 19, 2015 |
| Erdafitinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Imiquimod | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2008-05 |
| Nilotinib | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Oct 13, 2022 |
| Osimertinib | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Aug 17, 2015 |
| Ramucirumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | 2008-08 |
| Sintilimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Dec 23, 2020 |
| Adebrelimab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Mar 18, 2025 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.